DIGITIVA integrates the CORE 500 Digital Stethoscope and a smartphone application. Credit: Astellas Pharma US / PRNewswire.

Astellas Pharma US has partnered with Heritage Provider Network member, Desert Oasis Healthcare (DOHC), to pilot a new non-invasive digital health solution named DIGITIVA, to manage heart failure patients.

DIGITIVA integrates the CORE 500 Digital Stethoscope by Eko Health and a user-friendly smartphone application developed on the Welldoc platform.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Leveraging AI, it offers personalised digital coaching and educational resources from the American Heart Association.

The solution offers clinicians detailed patient reports, prepared by a clinical review team, which feature important cardio acoustic biomarkers such as S3 sounds and electromechanical activation time (EMAT), along with the physiological parameters. These reports are designed to support timely clinical interventions.

The collaboration is set to collect information to assess DIGITIVA’s impact on important clinical outcomes and cost-of-care metrics, which are significant for patients, healthcare providers, and the healthcare system on the whole.

Furthermore, patients will periodically fill out the Kansas City Cardiomyopathy Questionnaire (KCCQ) to evaluate their perceived symptoms, quality of life, and the effect of heart failure on their physical and social activities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company noted that in the coming weeks, selected patients under DOHC’s care are set to commence utilising DIGITIVA to manage their heart health in collaboration with their healthcare providers.

DIGITIVA was officially listed with the Food and Drug Administration (FDA) in September.

Astellas Pharma Rx+ Business accelerator and DIGITIVA Program lead Patrick Keenan said: “Implementing DIGITIVA in a real-world setting represents a significant achievement as the first SaMD and medical device offering from Astellas in the US.

“Working closely with Desert Oasis Healthcare, we look forward to demonstrating the potential of DIGITIVA to improve patient outcomes by supporting patients’ ability to take a more active role in managing their health, as well as providing clinicians with personalised information that can inform important clinical decisions.”

DOHC operations executive vice-president and the Heritage Provider Network ACO Brian Hodgkins said: “Placing patients at the centre of their care, DIGITIVA provides enhanced heart health data tracking, automated feedback and educational resources from home while equipping clinicians with patient-specific data potentially signalling when earlier intervention could be beneficial.”